Unlock the future of diabetes detection with Proinsulin Intact ELISA for early and accurate diagnosis.
Proinsulin, primarily produced in pancreatic β-cells, undergoes processing into insulin and C-peptide. While typically found in low concentrations in plasma of healthy individuals, insulin resistance (IR) or hyperglycemia prompts increased insulin secretion, leading to a disruption in secretion patterns. Consequently, plasma levels of intact proinsulin rise while insulin levels drop, serving as a specific biomarker for β-cell dysfunction and IR, also independently correlating with cardiovascular disease risk.
Figure 1: Intact versus total proinsulin.
- Total proinsulin = Intact proinsulin plus cleavage fragments (des32,33)
- Cleavage products are stable for hours, can be up to 30-50% of total proinsulin
- Exclude any possible reason for cleavage products (e.g. intake of fat food hours before blood collection)
- Intact proinsulin allows a better functional assessment of the ß-cell activity / dynamic
Transform diabetes detection with Proinsulin Intact ELISA.
- Early detection: Intact proinsulin indicates type 2 prediabetes before glucose changes. It predicts type 2 diabetes up to 4 years before clinical diagnosis.
- Insight into insulin resistance: Elevated intact proinsulin levels offer valuable information on insulin resistance, contributing to a comprehensive understanding of metabolic health.
- Diagnostic accuracy: The ELISA kit distinguishes itself by measuring intact proinsulin with high specificity, avoiding potential confounding factors present in total proinsulin assays.
- Clinical utility: Widely employed in reputable research and clinical studies1,2 ,Proinsulin Intact ELISA is recognized for its clinical relevance and reliability.
Figure 2:
Glucose, insulin and intact proinsulin profiles in oral glucose tolerance test (OGTT) for patients who developed T2D within 4 years from this test. Results are compared to healthy persons who did not develop T2D.
- Only intact proinsulin predicts later T2D development.3
- Glucose in mg/dl; insulin in μU/ml; intact proinsulin in pmol/l.
References:
- Sims, E. K., Geyer, S. M., Long, S. A., & Herold, K. C. (2023). High proinsulin: C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment. Diabetologia, 1-9.
- Sims, E. K., Bundy, B. N., Stier, K., Serti, E., Lim, N., Long, S. A., … & Type 1 Diabetes TrialNet Study Group. (2021). Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Science translational medicine, 13(583), eabc8980.
- 5. Pfützner A, Sachenheimer D, Lier A. Erhöhtes intaktes Proinsulin als früher Hinweis auf einen zukünftigen Typ-2-Diabetes. Diabetes,Stoffwechsel und Herz Band 27, Feb 2018
